Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open‐Label, Four‐Period Crossover Study Under Fasting and Fed Conditions
Clinical Pharmacology in Drug Development · 2026-06 · 15 (6)
DOI: 10.1002/cpdd.70071 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 29.05.2026. Verfasst von Jingyan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Health Industry, Sichuan Tourism University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Carbidopa, Catechols, Drugs, Generic, Levodopa. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Open Research Fund Project of Sichuan Tourism College, Key Program of Sichuan Tourism College.
Abstract (Originalsprache)
This study aimed to assess the pharmacokinetics, bioequivalence, and safety of a generic entacapone/levodopa/carbidopa (100/25/200 mg) tablet formulation compared to its reference listed drug (RLD, Stalevo) in healthy Chinese adults. A randomized, open‐label, single‐dose, four‐period crossover study was conducted under fasting and fed conditions, with a 5‐day washout. A total of 68 subjects were enrolled and randomly assigned (1:1) to receive a single oral dose of either the test or reference formulation. Plasma concentrations of analytes were quantified using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS), and key pharmacokinetic parameters (C max , AUC 0–t , AUC 0–∞ ) were calculated. Under both fasting and fed conditions, bioequivalence was assessed under both fasting and fed conditions using the reference‐scaled average bioequivalence (RSABE) or average bioequivalence (ABE) approach. For the key pharmacokinetic parameters (C max , AUC 0–t , and AUC 0–∞ ), the geometric mean ratios (GMRs) and their 90% confidence intervals (CIs) all fell within the 80.00%–125.00% range, or the one‐sided 95% upper confidence bound for the scaled difference was ≤0 and the point estimate of the GMR between the test and reference formulations fell within the 80.00%–125.00% range, thus confirming bioequivalence. Concomitant high‐fat food intake had a certain impact on the pharmacokinetics of each active ingredient. Adverse events (AEs) were mild, with no serious AEs reported, indicating comparable safety profiles. In conclusion, the generic formulation is bioequivalent to the RLD and demonstrates an acceptable safety profile in healthy Chinese subjects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Health Industry, Sichuan Tourism University, Chengdu, Sichuan, China.
- Phase I Clinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
- Shandong Jewim Pharmaceutical Co. Ltd., Shandong, China.
Förderung
- Open Research Fund Project of Sichuan Tourism College
- Key Program of Sichuan Tourism College
Zitieren
APA
Wang, J., Xu, Y., Tao, Y., Ma, X., Zou, Y., Yang, Z., & Lan, Y. (2026). Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open‐Label, Four‐Period Crossover Study Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development, 15(6). https://doi.org/10.1002/cpdd.70071
Vancouver
Wang J, Xu Y, Tao Y, Ma X, Zou Y, Yang Z, et al. Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open‐Label, Four‐Period Crossover Study Under Fasting and Fed Conditions. Clinical Pharmacology in Drug Development. 2026;15(6). doi:10.1002/cpdd.70071
BibTeX
@article{Wang2026,
author = {Wang, Jingyan and Xu, Yuan and Tao, Ye and Ma, Xuewei and Zou, Yang and Yang, Zhen and Lan, Yi},
title = {Pharmacokinetics and Tolerability of Entacapone, Levodopa, and Carbidopa Tablets in Healthy Chinese Subjects: A Randomized, Open‐Label, Four‐Period Crossover Study Under Fasting and Fed Conditions},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {6},
doi = {10.1002/cpdd.70071}
}
EUVIMED